MCID: HYP073
MIFTS: 42

Hypersensitivity Reaction Type Iv Disease

Categories: Cancer diseases, Immune diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Hypersensitivity Reaction Type Iv Disease

MalaCards integrated aliases for Hypersensitivity Reaction Type Iv Disease:

Name: Hypersensitivity Reaction Type Iv Disease 11 14
Immunoproliferative Disorders 43 71
Immunoproliferative Disease 11

Classifications:



External Ids:

Disease Ontology 11 DOID:2916
MeSH 43 D007160
SNOMED-CT 68 127071007
ICD10 31 C88 C88.9
UMLS 71 C0021070

Summaries for Hypersensitivity Reaction Type Iv Disease

Disease Ontology: 11 A hypersensitivity reaction disease that is characterized by a cell-mediated response to antigens, where Th1 helper T cells react with antigens on antigen-presenting cells and cause a delayed type immune response.

MalaCards based summary: Hypersensitivity Reaction Type Iv Disease, also known as immunoproliferative disorders, is related to cryoglobulinemia and autoimmune lymphoproliferative syndrome. An important gene associated with Hypersensitivity Reaction Type Iv Disease is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs D-Tyrosine and Antibodies have been mentioned in the context of this disorder. Affiliated tissues include t cells, small intestine and bone marrow, and related phenotypes are endocrine/exocrine gland and neoplasm

Related Diseases for Hypersensitivity Reaction Type Iv Disease

Diseases in the Hypersensitivity Reaction Type Iv Disease family:

Hypersensitivity Reaction Type Iii Disease

Diseases related to Hypersensitivity Reaction Type Iv Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 995)
# Related Disease Score Top Affiliating Genes
1 cryoglobulinemia 32.6 TNF IL6 IL10 IFNG HLA-DRB1
2 autoimmune lymphoproliferative syndrome 32.3 TNF IL2 IL10 ICOSLG CD8A CD4
3 sarcoidosis 1 31.8 TNF SERPINA3 PRTN3 NOD2 MIR155 IL6
4 monoclonal gammopathy of uncertain significance 30.8 IL6 ICOSLG CD8A CCR6
5 intestinal disease 30.7 SERPINA3 MIR155 ICOSLG CCR6
6 lymphoma, hodgkin, classic 30.7 MIR155 IL2 ICOSLG CCR6
7 duodenitis 30.6 TNF CRP CD8A CD4
8 lymphoproliferative syndrome 30.5 IL2 IL10 CCR6 CASP10
9 angioimmunoblastic t-cell lymphoma 30.5 MIR155 ICOSLG CD8A CD4 CCR6
10 amyloidosis 30.5 TNF SERPINA3 IL6 CRP
11 polyclonal hypergammaglobulinemia 30.4 SERPINA3 IL6 ICOSLG CRP CD8A CD4
12 lymphoma, non-hodgkin, familial 30.2 SERPINA3 MIR155 IL6 IL2 ICOSLG CD8A
13 leukemia, chronic lymphocytic 30.1 TNF MIR155 IL6 IL2 IL10 ICOSLG
14 deficiency anemia 30.0 TNF SERPINA3 PRTN3 IL6 IL2 IL10
15 crohn's disease 30.0 TNF SERPINA3 NOD2 IL6 IL2 IL10
16 myeloma, multiple 30.0 MIR155 IL6 IL2 ICOSLG CCR6
17 heavy chain disease 11.3
18 schnitzler syndrome 11.3
19 chronic nk-cell lymphocytosis 11.3
20 hilar lung neoplasm 10.5 CD8A CD4
21 adult acute lymphocytic leukemia 10.5 CD8A CD4 CCR6
22 mediastinum teratoma 10.5 CRP ACE
23 gastroduodenitis 10.5 CD8A CD4 CCR6
24 brawny scleritis 10.5 IFNG ACE
25 thymic dysplasia 10.5 ICOSLG CD8A CD4
26 spongiotic dermatitis 10.5 CD8A CD4 CCR6
27 autoimmune peripheral neuropathy 10.5 ICOSLG CD8A CD4
28 type 1 diabetes mellitus 23 10.5 TNF CD8A CD4
29 ventilation pneumonitis 10.5 CRP CD8A CD4
30 external pathological resorption 10.5 TNF IL6
31 necrotic uveal melanoma 10.5 IFNG CD8A
32 esophageal candidiasis 10.5 CD8A CD4 CCR6
33 autoimmune cholangitis 10.5 CD8A CD4 CCR6
34 oral tuberculosis 10.5 CD8A CD4
35 early yaws 10.5 CD8A CD4
36 evans' syndrome 10.5 CD8A CD4 CCR6
37 immunodeficiency 13 10.5 ICOSLG CD8A CD4
38 splenic abscess 10.5 CRP CD8A CD4
39 pneumonic tularemia 10.5 TNF CD8A CD4
40 paralytic poliomyelitis 10.5 SERPINA3 CD8A CD4
41 nocardiosis 10.5 TNF CRP CD4
42 scabies 10.5 CD8A CD4 CCR6
43 opportunistic bacterial infectious disease 10.5 TNF CRP CD4
44 hepatosplenic t-cell lymphoma 10.5 TNF CD8A CD4
45 toxic megacolon 10.5 TNF CRP CCR6
46 ocular tuberculosis 10.5 IFNG CD4 ACE
47 inflammatory bowel disease 5 10.5 NOD2 ICOSLG CCR6
48 selective immunoglobulin deficiency disease 10.5 ICOSLG CD8A CD4
49 mite infestation 10.5 CD8A CD4 CCR6
50 chronic pyelonephritis 10.5 SERPINA3 CRP ACE

Graphical network of the top 20 diseases related to Hypersensitivity Reaction Type Iv Disease:



Diseases related to Hypersensitivity Reaction Type Iv Disease

Symptoms & Phenotypes for Hypersensitivity Reaction Type Iv Disease

MGI Mouse Phenotypes related to Hypersensitivity Reaction Type Iv Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.96 ACE BTNL2 CD4 CD8A IFNG IL10
2 neoplasm MP:0002006 9.87 ACE BTNL2 IFNG IL10 IL2 IL6
3 immune system MP:0005387 9.86 ACE BTNL2 CCR6 CD4 CD8A CRP
4 digestive/alimentary MP:0005381 9.81 BTNL2 CD4 IFNG IL10 IL2 IL6
5 hematopoietic system MP:0005397 9.5 ACE BTNL2 CCR6 CD4 CD8A ICOSLG

Drugs & Therapeutics for Hypersensitivity Reaction Type Iv Disease

Drugs for Hypersensitivity Reaction Type Iv Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 19)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 3 133585-56-5, 556-02-5, 60-18-4 1153 6057
2 Antibodies Phase 3
3 Immunoglobulins Phase 3
4
Rituximab Approved Phase 2 174722-31-7
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3 3680
6
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 3003 5743
7
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
8
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
9
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
10
Fludarabine Approved Phase 1, Phase 2 75607-67-9, 21679-14-1 30751 657237
11 gamma-Globulins Phase 2
12 Rho(D) Immune Globulin Phase 2
13 Immunoglobulins, Intravenous Phase 2
14 Antineoplastic Agents, Alkylating Phase 1, Phase 2
15 Antirheumatic Agents Phase 1, Phase 2
16 Immunosuppressive Agents Phase 1, Phase 2
17 Alkylating Agents Phase 1, Phase 2
18 Immunologic Factors Phase 1, Phase 2
19 Bendamustine Hydrochloride Phase 1

Interventional clinical trials:

(show all 11)
# Name Status NCT ID Phase Drugs
1 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Not yet recruiting NCT05431179 Phase 3 Zilovertamab;Ibrutinib;Placebo
2 A Non-randomized, Open-label, Phase II Study of Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not Suitable for Transplantation Unknown status NCT03373019 Phase 2 Chidamide combined with R-GDP
3 Study of Immune Responses and Safety of Recombinant CD40 Ligand in Patients With X-Linked Hyper IgM Syndrome Completed NCT00001145 Phase 2 Bacteriophage;rhuCD40L;KLH
4 Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma Recruiting NCT02690545 Phase 1, Phase 2
5 Administration of Autologous CAR-T Cells Targeting the CD19 Antigen and Containing the Inducible caspase9 Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Recruiting NCT03016377 Phase 1, Phase 2 Rimiducid;Cyclophosphamide;Fludarabine
6 A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting Active, not recruiting NCT03744676 Phase 2
7 Phase I Study of the Administration of T Lymphocytes Co-Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin Lymphoma and Cutaneous T-Cell Lymphoma Recruiting NCT03602157 Phase 1 Bendamustine;Fludarabine
8 A Phase I Study of Autologous Activated T-cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Relapsed/Refractory B-cell Lymphoma Recruiting NCT03696784 Phase 1 Bendamustine;Fludarabine;AP1903;Cyclophosphamide
9 Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS) Active, not recruiting NCT02663297 Phase 1 ATLCAR.CD30 cells
10 A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting. Active, not recruiting NCT04309084 Phase 1
11 Compassionate Use Administration of Autologous CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch No longer available NCT03594162 iC9-CAR19 cells;AP1903;Cyclophosphamide;Fludarabine

Search NIH Clinical Center for Hypersensitivity Reaction Type Iv Disease

Cochrane evidence based reviews: immunoproliferative disorders

Genetic Tests for Hypersensitivity Reaction Type Iv Disease

Anatomical Context for Hypersensitivity Reaction Type Iv Disease

Organs/tissues related to Hypersensitivity Reaction Type Iv Disease:

MalaCards : T Cells, Small Intestine, Bone Marrow, Bone, Lung, Skin

Publications for Hypersensitivity Reaction Type Iv Disease

Articles related to Hypersensitivity Reaction Type Iv Disease:

(show all 42)
# Title Authors PMID Year
1
Age-specific incidence rate of immunoproliferative disease and multiple myeloma in the world. 62
34791334 2021
2
[An immunoproliferative disease of the small intestine revealed by acute intussusception: report of a case]. 62
24932323 2014
3
Castleman's disease--a rare disease with varying presentation. 62
23360031 2012
4
Morphologic features of extrahepatic manifestations of hepatitis C virus infection. 62
22919404 2012
5
The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. 62
22223085 2012
6
Pink pigtail in a skin biopsy: What is your diagnosis? 62
21272503 2011
7
Structural genomics of the Epstein-Barr virus. 62
17001105 2006
8
Marginal zone lymphoma. 62
16507274 2006
9
Patient with immunoproliferative disease and lung carcinoma: a case report. 62
15637671 2005
10
The role of somatostatin analogs in the management of immunoproliferative disease. 62
15233223 2003
11
Viral infections of the gastrointestinal tract. 62
10980963 1999
12
[Immunoproliferative disease of the small intestine. A case of polymeric IgA with evolution to lymphoma]. 62
9808897 1998
13
Crystalloidal paraprotein deposits in the cornea: an ultrastructural study of two new cases with tubular crystalloids that contain IgG kappa light chains and IgG gamma heavy chains. 62
9205998 1997
14
Risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. 62
9161471 1997
15
[Immune dysfunctions in patients with immunoproliferative disease]. 62
7561363 1995
16
[Immunoproliferative disease of the small intestine, associated with IgA kappa monoclonal gammapathy with good clinical and histologic response to the treatment with tetracyclines]. 62
7654912 1994
17
[Immunoproliferative disease of the small intestine. Report of a case]. 62
8318283 1993
18
[Deficiency polyneuropathy secondary to immunoproliferative disease of the small intestine]. 62
1493062 1992
19
[Immunoproliferative disease of the small intestine. A rare differential diagnosis of Crohn's disease]. 62
1874129 1991
20
[Bence-Jones proteinuria in multiple sclerosis: a possible indicator of disease activity]. 62
2075283 1990
21
[Alpha heavy chain disease: a clinical study of 3 cases and review of the literature]. 62
2115016 1990
22
The clinical spectrum of pure Bence Jones proteinuria. A study of 66 patients. 62
3179959 1988
23
[Immunoproliferative disease of the small intestine. Description of a case with secretion of complete IgA]. 62
3148986 1988
24
[Clinico-radiologic correlations in 2 cases of immunoproliferative disease of the small intestine]. 62
3347777 1988
25
Immunoperoxidase study on paraffin sections of gastrointestinal lymphoreticular lesions. 62
3329410 1987
26
[Immunoproliferative disease of the small intestine with development to B cell immunoblastic sarcoma. Presentation of a case]. 62
3500490 1987
27
Alpha-chain disease: an immunoproliferative disease of the secretory immune system. 62
6408973 1983
28
[Radiological treatment of non-Hodgkin lymphoma as an immunoproliferative disease]. 62
6855427 1983
29
Quantitative bone histology in the hypercalcemia of malignant disease. 62
7130337 1982
30
[Immunoproliferative disease of the small intestine]. 62
6984965 1982
31
[Apropos of a case of idiopathic cryoagglutininemia with cryoglobulinemia and bone marrow lymphoplasmacytoid infiltration]. 62
6793936 1981
32
Immunoproliferative disease of the gastrointestinal tract: a report of five cases. 62
7221698 1980
33
[Immunoproliferative disease of the small intestine and heavy alpha chain disease. Contribution of a new case of delayed appearance with a favorable response to tetracycline]. 62
6769139 1980
34
Plasma exchange: a selective form of blood-letting. 62
160005 1979
35
[Immunology and gastroenterology]. 62
456968 1979
36
[Simultaneous occurrence of pure red cell aplasia and malignant lymphoma (author's transl)]. 62
301596 1977
37
[Clinico-pathological study of a case of alpha chain disease]. 62
823471 1976
38
[Amyloidosis: an immunoproliferative disease]. 62
4203558 1973
39
[Immunoproliferative disease with a complex immune defect]. 62
4541866 1972
40
[Myeloma, an immunoproliferative disease]. 62
5120035 1971
41
Three cases of malignant immunoproliferative disease. 62
4097589 1970
42
Equine infectious anemia: a model of immunoproliferative disease. 62
5690595 1968

Variations for Hypersensitivity Reaction Type Iv Disease

Expression for Hypersensitivity Reaction Type Iv Disease

Search GEO for disease gene expression data for Hypersensitivity Reaction Type Iv Disease.

Pathways for Hypersensitivity Reaction Type Iv Disease

Pathways related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

(show all 46)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 BTNL2 CASP10 CCR6 CD4 CD8A CRP
2
Show member pathways
13.3 CD4 HLA-DRB1 IFNG IL10 IL2 IL6
3
Show member pathways
13.27 TNF IL6 IL2 IL10 CD4 CCR6
4
Show member pathways
12.82 TNF MIR155 IL6 IL2 CASP10
5
Show member pathways
12.59 TNF IL6 IL2 IL10 IFNG CD4
6 12.57 TNF IL2 IL10 IFNG CD8A
7
Show member pathways
12.37 ICOSLG HLA-DRB1 CD8A CD4
8
Show member pathways
12.25 IL2 ICOSLG HLA-DRB1 CD4
9
Show member pathways
12.16 TNF IL2 IL10 IFNG HLA-DRB1 CD8A
10 12.11 TNF IL6 IL10 IFNG
11 12 TNF IL6 IL2 IFNG
12
Show member pathways
11.98 IL2 IFNG CD8A CD4
13
Show member pathways
11.93 TNF IL6 IL2 IL10 IFNG CD4
14 11.93 TNF IL6 IL2 IL10 IFNG CD8A
15 11.89 TNF IL2 IL10 IFNG HLA-DRB1
16
Show member pathways
11.79 IL6 HLA-DRB1 CRP CD8A CD4
17 11.77 CD4 IFNG IL10 IL2 IL6
18 11.75 IL6 IL2 IFNG
19 11.75 IFNG IL10 IL2 IL6
20 11.74 CD4 IFNG IL2 IL6
21
Show member pathways
11.7 TNF IL6 IL2 IFNG
22 11.7 CCR6 CD4 CD8A IFNG IL10 IL2
23
Show member pathways
11.69 TNF IL2 IFNG
24 11.68 TNF MIR155 IL6 IL10
25 11.65 TNF IL6 IL10
26
Show member pathways
11.62 TNF NOD2 IL6 IL2 IL10 IFNG
27 11.58 IFNG IL2 IL6
28 11.58 TNF NOD2 IL6 IFNG
29 11.57 TNF IL6 IL2 IL10 IFNG CD8A
30 11.56 TNF IL2 IL10 IFNG HLA-DRB1 CD4
31 11.52 TNF IL6 IL10
32 11.52 IL2 IL10 IFNG CD4
33 11.5 TNF IL6 IFNG
34 11.4 IL10 HLA-DRB1 CD4
35
Show member pathways
11.39 TNF IL2 IL10 IFNG
36 11.37 TNF IL6 IL10
37 11.35 TNF IL6 IL2 IL10 IFNG ICOSLG
38 11.33 IFNG IL6 TNF
39 11.24 IL2 IFNG CD4
40 11.22 IL2 IL10 IFNG
41 11.08 TNF IL6 CRP
42 10.97 IL2 IFNG CD4
43 10.7 IL2 IFNG
44 10.69 IL6 IL2
45 10.63 TNF IL6 IL2 IL10 IFNG HLA-DRB1
46
Show member pathways
10.37 TNF IL6

GO Terms for Hypersensitivity Reaction Type Iv Disease

Cellular components related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.53 TNF ICOSLG HLA-DRB1 CD8A CD4 CCR6

Biological processes related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 10.36 IL2 IFNG ICOSLG HLA-DRB1 CD8A CD4
2 positive regulation of inflammatory response GO:0050729 10.19 ACE IFNG IL2 TNF
3 T cell receptor signaling pathway GO:0050852 10.19 BTNL2 CD8A HLA-DRB1 ICOSLG
4 positive regulation of interleukin-6 production GO:0032755 10.18 TNF NOD2 IL6 IFNG
5 defense response to Gram-positive bacterium GO:0050830 10.16 CRP IL6 NOD2 TNF
6 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.16 CASP10 CD4 HLA-DRB1 NOD2 TNF
7 immune system process GO:0002376 10.1 NOD2 IL2 ICOSLG HLA-DRB1 CD8A CD4
8 acute-phase response GO:0006953 10.09 SERPINA3 IL6 CRP
9 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.08 TNF IL6 IL10
10 liver regeneration GO:0097421 10.04 TNF IL6 IL10
11 positive regulation of MAPK cascade GO:0043410 10.02 CD4 HLA-DRB1 IL6 NOD2 TNF
12 positive regulation of immunoglobulin production GO:0002639 10 IL10 IL2 IL6
13 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.99 TNF NOD2 IL6
14 positive regulation of interleukin-17 production GO:0032740 9.97 NOD2 IL6 IL2
15 macrophage differentiation GO:0030225 9.95 IFNG HLA-DRB1 CD4
16 negative regulation of cytokine production involved in immune response GO:0002719 9.93 TNF IL10
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.92 TNF IL6 IL2 IFNG
18 negative regulation of interleukin-18 production GO:0032701 9.9 NOD2 IL10
19 positive regulation of plasma cell differentiation GO:1900100 9.86 IL2 IL10
20 positive regulation of interleukin-1 beta production GO:0032731 9.86 TNF NOD2 IL6 IFNG
21 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.85 TNF IFNG
22 positive regulation of nitrogen compound metabolic process GO:0051173 9.84 TNF IFNG
23 positive regulation of vitamin D biosynthetic process GO:0060557 9.73 TNF IFNG
24 chronic inflammatory response to antigenic stimulus GO:0002439 9.71 TNF IL10
25 humoral immune response GO:0006959 9.65 TNF IL6 IFNG HLA-DRB1 CCR6
26 negative regulation of lipid storage GO:0010888 9.63 CRP IL6 TNF
27 immune response GO:0006955 9.47 TNF IL6 IL2 IL10 IFNG HLA-DRB1

Molecular functions related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.32 TNF IL6 IL2 IL10 IFNG

Sources for Hypersensitivity Reaction Type Iv Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....